135 results
Page 3 of 7
8-K
EX-99.1
a9bj03ckjop1dgotxroj
11 Feb 21
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
9cgf5t6f052188oa8cv
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
w2i62zrqu7
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
EX-3.1
ngo0wv4u
17 Dec 20
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
EX-99.1
2v44ac4 em
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.2
871e z2b21hhk9no28sq
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
n8z a0yrfes4wirvuo
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
kddki9nxw3pazq
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
8-K
EX-99.1
put xidkh2c4w
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
424B5
n6ry4d60zaf5rhe41e4
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
vlqi0mv6y ongxoj0n9z
2 Mar 20
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
cwuz0xmwptkuf
2 Mar 20
Other Events
7:05am
8-K
EX-99.1
5ow1ztyf5dwpqj6nz
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-99.1
jqa jlmcjpx
13 Jan 20
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
7:12am
8-K
EX-99.1
chiwqompmeroazi mz
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am